China Biologic Produ
(CBPO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2013 | 12-2012 | 09-2012 | 06-2012 | 03-2012 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 21,912 | 65,972 | 55,784 | 37,311 | 17,718 |
| Depreciation Amortization | 1,817 | 8,881 | 6,620 | 3,807 | 1,853 |
| Income taxes - deferred | 535 | 1,127 | -516 | 26 | 98 |
| Accounts receivable | -3,294 | 5,690 | 1,872 | -4,692 | -7,934 |
| Accounts payable and accrued liabilities | 26 | -2,185 | -1,104 | -1,546 | -881 |
| Other Working Capital | -3,741 | -5,929 | 3,324 | -7,942 | -10,265 |
| Other Operating Activity | 4,775 | -2,458 | -1,195 | 5,106 | 7,620 |
| Operating Cash Flow | $22,030 | $71,097 | $64,786 | $32,069 | $8,208 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | N/A | -2,731 | -1,349 | N/A |
| PPE Investments | -4,975 | -13,803 | -7,437 | -5,099 | -2,326 |
| Purchase Sale Intangibles | -802 | -14,059 | -797 | -797 | -319 |
| Other Investing Activity | -802 | -12,950 | -12,908 | -241 | -319 |
| Investing Cash Flow | $-5,777 | $-26,753 | $-23,076 | $-6,689 | $-2,645 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | 11,076 | 11,076 | N/A | N/A |
| Common Stock Issued | 1,816 | 5,227 | 4,620 | 4,500 | N/A |
| Dividend Paid | -4,397 | -7,121 | -4,379 | -4,379 | -4,383 |
| Other Financing Activity | -5,150 | -14,287 | -11,106 | -11,106 | -6,352 |
| Financing Cash Flow | $-7,732 | $-5,104 | $211 | $-10,985 | $-10,735 |
| Exchange Rate Effect | 579 | 957 | 391 | 680 | 734 |
| Beginning Cash Position | 129,609 | 89,412 | 89,412 | 89,412 | 89,412 |
| End Cash Position | 138,710 | 129,609 | 131,723 | 104,487 | 84,975 |
| Net Cash Flow | $9,101 | $40,198 | $42,311 | $15,075 | $-4,437 |
| Free Cash Flow | |||||
| Operating Cash Flow | 22,030 | 71,097 | 64,786 | 32,069 | 8,208 |
| Capital Expenditure | -4,977 | -13,886 | -7,437 | -5,099 | -2,326 |
| Free Cash Flow | 17,053 | 57,211 | 57,349 | 26,971 | 5,882 |